Manufacturing

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Articles

Packaging and transporting large quantities of COVID-19 vaccines pose challenges for the cold chain.

Accelerating Technology Adoption to Track the Cold Chain

Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.

Baxter and Novavax Enter into COVID-19 Vaccine Sterile Manufacturing Agreement

The company plans to deliver initial doses by mid-2021, and Australia will have the option to purchase up to 10 million additional doses through the agreement. 

Novavax Enters into Agreement with the Commonwealth of Australia for 51 Million Doses of its COVID-19 Vaccine

Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.

Bayer and CureVac to Collaborate on COVID-19 Vaccine Candidate

The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States. 

Moderna and Recipharm Announce COVID-19 Vaccine Supply Agreement 

Part of Operation Warp Speed, the trial will enroll 30,000 people ages 18 to 64 and 65 and older at 115 sites.

Phase III Trial of Novavax COVID-19 Trial Open for Enrollment in the US and Mexico

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Ensuring Vaccine Supply Meets Global Needs

Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.

Oxford/AstraZeneca Vaccine Granted Emergency Use Approval in UK

Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation. 

Second COVID-19 Vaccine Granted EUA, Ships for Immediate Use

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Manufacturing, Vaccines